Summary
| Direction in Lyme Disease | ↑ Elevated — higher than in the comparison group |
|---|---|
| Category | Serologic |
| Also described as | Enzyme immunoassay — tier 1 |
| Compared against | Uninfected |
| Associated symptoms | Active or past Lyme infection |
| Test type | Blood test (serum / plasma / whole blood) |
| Source | CDC 2024 — doi:10.1016/j.idc.2021.05.001 |
| Condition atlas | Lyme Disease Biomarker Atlas |
Trials, interventions and tests
In clinical-trial registrations this marker maps to the outcome term Change in the ALC from Screening, INT1, FU1.3, INT2, FU2.3, FU2.4, FU2.5, and EOS. (25 registered trials use a matching outcome measure).
Clinical trials using B. burgdorferi EIA (screening) as an outcome
- NCT07388550: Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I) (Not Yet Recruiting)
Outcome measure: The primary outcome of this study is to determine the safety of a single dose of intravenous Pembrolizumab in participants with neurological post-acute sequalae of SARS-CoV-2 infection. - NCT06974084: A Multi-Center, Individually-Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Superiority Trial to Evaluate the Efficacy of the Combination of Maraviroc and Atorvastatin for the Treatment of Subjects With Long COVID (Not Yet Recruiting)
Outcome measure: Fatigue - NCT07627815: Evaluating the Safety and Efficacy of PNMR as Treatment for Long COVID (Recruiting)
Outcome measure: Change in distance walked on the 6-minute walk test (6MWT) after 6 weeks of treatment. - NCT07123727: A Study to Examine Anktiva for the Treatment of COVID-19. (Recruiting)
Outcome measure: Percent increase or decrease change in the Absolute lymphocyte count (as measured on CBC) from Screening to End Of Study with various timepoints. - NCT07108036: A Study to Assess Anktiva in Patients With Long Covid-19. (Recruiting)
Outcome measure: Change in the ALC from Screening, INT1, FU1.3, INT2, FU2.3, FU2.4, FU2.5, and EOS. - NCT06404073: RECOVER-ENERGIZE Platform Protocol_Appendix B (Structured Pacing (PEM)) (Completed)
Outcome measure: Change in orthostatic hypotension, as measured by the Modified Orthostatic Hypotension Questionnaire (mOHQ) - NCT05846126: Digital Multimodal Rehabilitation for People With Post-acute COVID-19 Syndrome. (Completed)
Outcome measure: Differences between groups in scores of global cognition - NCT05890534: Pycnogenol® in Post-COVID-19 Condition (Completed)
Outcome measure: Functional exercise capacity
17 more trials reference this marker.
Commercial test availability
Lyme Disease Antibody Screen (EIA) — commercial laboratory test.
Links are for reference only; availability, specimen requirements and coverage vary by location.
Related Serologic markers in Lyme Disease
- IgG immunoblot (≥5 of 10 bands) ↑
- IgM immunoblot (≥2 of 3 bands) ↑
- C6 peptide ELISA (VisE) ↑
- Anti-VlsE antibodies ↑
- Anti-OspC antibodies ↑
- Anti-OspA antibodies ↑
- Anti-p41 (flagellin) antibodies ↑
- Synovial fluid anti-Bb antibodies ↑
Full list: Lyme Disease Biomarker Atlas.
Frequently asked questions
Is B. burgdorferi EIA (screening) high or low in Lyme Disease?
Elevated. Studies summarised in the OSMF atlas report higher B. burgdorferi EIA (screening) in Lyme Disease than in Uninfected. Source: CDC 2024.
What symptoms is B. burgdorferi EIA (screening) associated with in Lyme Disease?
The cited literature associates this marker with Active or past Lyme infection. These are population-level associations and do not mean the marker causes the symptoms.
Which test measures B. burgdorferi EIA (screening)?
It is measured as a blood test (serum / plasma / whole blood). Commercial laboratories such as LabCorp, Quest Diagnostics list an orderable assay.
Is one abnormal B. burgdorferi EIA (screening) result diagnostic of Lyme Disease?
No. No single biomarker is diagnostic of Lyme Disease. B. burgdorferi EIA (screening) findings come from group comparisons, overlap considerably between patients and controls, and vary with study design, timing and comparison group. A result should be interpreted by a clinician alongside symptoms, history and other tests.
Cite this page
Subscribe on Substack
Last reviewed: 2026-06-29 · Page generated from lyme.json · Browse: Lyme Disease atlas · Biomarker Index · All marker pages
Disclaimer: This page is an educational synthesis of published, peer-reviewed research and is not medical advice. Biomarker findings vary across studies with case definitions, comparison groups, timing and assay methods. Direction of change reflects the predominant finding in the cited source and does not establish a diagnostic threshold. Discuss any test result with a qualified clinician.